<DOC>
	<DOC>NCT02472886</DOC>
	<brief_summary>This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in adults with chronic hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>Participants who failed treatment in Study GSUS3340119 who meet relevant inclusion/exclusion criteria are eligible for retreatment in this study Chronic genotype 1 HCV infection HCV treatmentnaive HCV RNA &gt; 10,000 IU/mL at screening Absence of cirrhosis Screening laboratory values within defined thresholds Use of two effective contraception methods if female of childbearing potential or sexually active male Pregnant or nursing female or male with pregnant female partner Infection with hepatitis B virus (HBV) Current or prior history of clinical hepatic decompensation Chronic use of systemic immunosuppressive agents History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol For HIV1/HCV coinfected individuals: Opportunistic infection within 6 months prior to screening Active, serious infection (other than HIV1 or HCV) requiring parental antibiotics, antivirals or antifungals within 30 days prior to baseline Treatment with an antiretroviral (ARV) regimen other than one of those listed in the study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HCV genotype 1</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>ledipasvir</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C, Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>